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INTRODUCTION
Q-fever is an infectious disease caused by Coxiella
burnetii, an obligate intracellular parasite trans-
mitted to humans through contact with infected
domestic animals. The present study, performed
in 2007, aimed to evaluate the seroprevalence of
C. burnetii in healthy individuals aged 1 day to
90 years from northern Greece.
MATERIALS AND METHODS
Serum samples were collected from 1007 healthy individuals
living in rural and urban areas of the 16 prefectures in
northern Greece. The number of individuals tested from each
prefecture was proportional to the population of the respective
region. The following information was obtained from each
person: sex, age, occupation, loss of weight, contact with
animals, consumption of unpasteurized products, and history
of pneumonia, prolonged fever, jaundice, hepatitis, anaemia,
pericarditis, central nervous system infection, osteomyelitis,
lymphadenopathy, valvulopathy, and endocarditis. All partic-
ipants were grouped into seven age groups: 1–10, 11–20, 21–30,
31–40, 41–50, 51–60 and >60 years. The sera were stored at –
70C until required for analysis. All sera were examined using
the C. burnetii IgG (phase I–II) indirect immunoﬂuorescence
antibody test kits (Focus Technologies, Cypress, CA, USA)
according to the manufacturer’s instructions. The serum
samples were initially diluted 1 ⁄ 64. Any serum found to be
positive at the initial dilution was further titrated. Titres of
1 ⁄ 64 were considered to be positive.
Statistical analysis was performed using SPSS for Windows
v. 15.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
Of the 1007 subjects examined, 76 (7.5%) were
seropositive for IgG phase I antibodies to C. bur-
netii (Table 1). The prevalence of antibodies was
slightly different in the 16 prefectures. The age of
the seropositive people was (mean age ± stan-
dard deviation) 37.72 ± 19.71 years, whereas the
seronegative people had an age of 44.24 ± 18.267
years (p <0.01). The overall prevalence of
C. burnetii did not differ signiﬁcantly between
males (4.9%) and females (2.7%) or between age
groups. No seropositivity was observed in the
1–10 year-old age group.
There was a statistically signiﬁcant difference
in IgGI seropositivity (p <0.005) among the com-
pared professional groups; it was higher among
farmers and stock breeders (14.4%). History of
jaundice, hepatitis, anaemia, pneumonia, endo-
carditis, neurological disorders, fever, loss of
weight, lymphadenopathy, valvulopathy and
osteomyelitis among the seropositive individuals
was found in 14.6% (not signiﬁcant (NS)), 25.4%
(p <0.005), 17.0% (p <0.01), 36.6% (p <0.005),
6.7% (NS), 14.9% (p <0.05), 44.9% (p <0.005),
13.3% (NS), 11.6% (NS), 21.4% (p <0.01), and
10.0% (NS), respectively in the seropositive group
Table 1. Prevalence of antibodies to C. burnetii in 16
prefectures of northern Greece
Positive for
C. burnetii n (%)
Total no.
examined sera
(1) Thessaloniki 4 (6,2) 65
(2) Chalkidiki 3 (4,6) 65
(3) Hmathia 4 (6,3) 63
(4) Kilkis 4 (6,1) 66
(5) Pella 2 (3,4) 58
(6) Pieria 6 (10,9) 55
(7) Serres 2 (2,9) 69
(8) Kozani 5 (7,4) 68
(9) Kastoria 3 (4,8) 62
(10) Florina 6 (9,4) 64
(11) Grevena 8 (12,7) 63
(12) Kavala 3 (4,7) 64
(13) Drama 5 (8,2) 61
(14) Xanthi 6 (8,8) 68
(15) Rodopi 7 (11,9) 59
(16) Evros 8 (14) 57
Total 76 (7,5) 1007
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(Table 2). Contact with animals was found to be a
major risk factor, as 44 seropositive subjects
(18.4%) had a history of contact, mainly with
sheep (p <0.005). Consumption of unpasteurized
products was not found to be major risk factor in
the acquisition of Q-fever (NS). Titres of 1 ⁄ 64,
1 ⁄ 128, 1 ⁄ 256, 1 ⁄ 512 and 1 ⁄ 1024 were found in
3.7%, 2.2%, 1.3%, 0.2% and 0.2%, respectively.
No chronic form of Q-fever was detected.
DISCUSSION
In Greece, in 1946 Gaminopetros diagnosed Q-
fever in German soldiers who had febrile illness,
known as the ‘Balkan ﬂu’. Since then, cases of Q-
fever have been reported sporadically [1]. A study
on the aetiology of C. burnetii in atypical pneu-
monia in northern Greece demonstrated 4.7%
seropositivity to C. burnetii among patients with
atypical pneumonia [2]. A retrospective study,
undertaken in Crete, revealed that the prevalence
of C. burnetii antibodies in 1.298 patients was
7.6% [3].
Our study showed that 7.5% of the population
of northern Greece are IgG-positive for C. burnetii.
This prevalence is similar to that in other Med-
iterranean countries, such as Spain, France, Croa-
tia, and Bosnia [4].
Men appear to have antibodies more often than
women, and this could be explained by the fact
that men are more often involved in farming [5].
Q-fever in children was not reported in our study.
The fact that adolescents are more prone to
infection than children is consistent with other
data, where an age-related increase in the inci-
dence of Q-fever infection is evident [5].
The highest seropositivity was observed among
farmers and stock breeders [5]. This ﬁnding is in
agreement with those of other surveys, and can be
attributed to more frequent exposure. The sero-
prevalence did not vary signiﬁcantly among the
prefectures studied. This observation could be
explained by the fact that in rural areas, people are
often occupied in outdoor activities. Therefore,
more studies are required to further characterize
the life conditions and the epidemiology of Q-fever
infection in animals and in humans in our area.
The titres detected in this study were mostly
low (1 ⁄ 64 to 1 ⁄ 256). This ﬁnding is in agreement
with other surveys based on the indirect immu-
noﬂuorescence method.
Our data indicate a wide distribution of C. bur-
netii in northern Greece, and conﬁrm the fact that
Q-fever remains a signiﬁcant health problem in
many parts of the world.
Q-fever should be considered as an aetiological
diagnosis among patients presenting with clinical
manifestations such as pneumonia, hepatitis, and
prolonged fever.
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Table 2. Q fever in northern Greece: clinical history of
the 1007 subjects examined
Clinical history IgG Positive no (%)
Jaundice 6 (14,6) NS
Hepatitis 18 (25,4) p < 0.005
Anemia 8 (17) p < 0.01
Pneumonia 26 (36,6) p < 0.005
Endocarditis 1 (6,7) NS
Neur. disorders 10 (14,9) p < 0.05
Fever 31 (44,9) p < 0.005
Weight 6 (13,3) NS
Lymphadenopathy 11 (11,6) NS
Valvulopathy 6 (21,4) p < 0.01
Osteomyelitis 1 (10) NS
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